GemPharmatech Partners with Leading Cancer Center to Boost Antibody Discovery Efforts

GemPharmatech and Memorial Sloan Kettering Collaborate for Antibody Discovery

In a significant advancement for cancer research, GemPharmatech, a frontrunner in preclinical research solutions, has announced a strategic collaboration with the prestigious Memorial Sloan Kettering Cancer Center (MSK). This partnership aims to expedite the discovery of novel therapeutic antibodies critical for combating cancer.

GemPharmatech's comprehensive preclinical services will bolster the efforts of MSK researchers, who will utilize the NeoMab® platform. This cutting-edge transgenic mouse model is designed specifically to facilitate the rapid generation of fully human therapeutic antibodies. The collaboration sets out to enhance the development of antibodies that target high-value cancer therapies, potentially revolutionizing treatment for patients facing urgent medical needs.

Dr. Xiang Gao, founder of GemPharmatech, expressed optimism regarding this collaboration, stating, "Our mission has always been to enable transformative biomedical research through innovative mouse models and technologies. Collaborating with MSK on antibody discovery represents a powerful opportunity to combine scientific excellence with cutting-edge mouse models such as NeoMab®. Together, we can accelerate the development of novel therapeutics that address some of the most urgent challenges in cancer treatment."

The NeoMab® model, which is part of the world's largest library of genetically engineered mouse models (GEMMs), boasts the full variable gene repertoire of human heavy and kappa light chains within a BALB/c background. This unique design allows for the fast-track production of diverse and high-affinity fully human antibodies, eliminating the traditionally lengthy sequencing and humanization steps usually required.

"This collaboration underscores our mission to provide the global research community with advanced platforms to accelerate innovations in drug discovery," remarked Dr. Brandy Wilkinson, CEO of GemPharmatech. "We are excited to support MSK's pioneering work in oncology research with the NeoMab® platform. It is an honor to contribute to their scientific mission and to help advance antibody programs with the potential to transform therapies and improve patient outcomes worldwide."

GemPharmatech asserts that with more than 25,000 strains of knockout, conditional knockout, humanized, and immunodeficient mice, it stands as a key player in accelerating therapeutic innovation across various domains, including oncology and immunology. By providing services such as custom model generation and microbiome research, the organization is positioned to meet the growing demands of biomedical research on a global scale.

This collaborative venture not only emphasizes GemPharmatech's commitment to pioneering biomedical solutions but also highlights MSK’s role in the forefront of cancer research, illustrating the powerful union of advanced technological capabilities with clinical expertise. As the demand for innovative cancer therapies continues to grow, partnerships like this represent a beacon of hope for advancements in patient care and treatment options.

For more information about GemPharmatech and their extensive offerings, visit their website at www.gempharmatech.com.